Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat

Synapse

Volumn 36, Issue 3, 2000, Pages 205-221

  Gobert, Alain ^a   Rivet, Jean Michel ^a   Lejeune, Françoise ^a   Newman Tancredi, Adrian ^a   Adhumeau Auclair, Agnes ^a   Nicolas, Jean Paul ^a   Cistarelli, Laetitia ^a   Melon, Christophe ^a   Millan, Mark J ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Depression; Frontal cortex; Locus coeruleus; Schizophrenia; Ventrotegmental area

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 METHYL 5 ISOTHIAZOLYL)UREA; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 ( CHLORO 5 FLUOROINDOL 1 YL) 1 METHYLETHYLAMINE; 2 CHLORO 5 FLUOROINDOL 1 YL 1 METHYLETHYLAMINE FUMARATE; 6 CHLORO 5 METHYL 1 [6 (2 METHYLPYRIDIN 3 YLOXY)PYRIDIN 3 YL CARBAMOYL] INDOLINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; DOPAMINE; NORADRENALIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ADRENERGIC NERVE CELL; ADRENERGIC TRANSMISSION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIALYSIS; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG RECEPTOR BINDING; ELECTROPHYSIOLOGY; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM;

ANIMALS; CEREBRAL CORTEX; CORPUS STRIATUM; DIALYSIS; DOPAMINE; ELECTROPHYSIOLOGY; EPINEPHRINE; EXTRACELLULAR SPACE; FRONTAL LOBE; LOCUS COERULEUS; MALE; NEURONS; NUCLEUS ACCUMBENS; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; SEROTONIN; TEGMENTUM MESENCEPHALI;

EID: 0034213062     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(20000601)36:3<205::AID-SYN5>3.0.CO;2-D     Document Type: Article

References (106)

1. Aghajanian GK, Cedarbaum JM, Wang RY. 1977. Evidence for a norepinephrine-mediated collateral inhibition of locus coeruleus neurons. Brain Res 136:570-577.
2. 2C receptor. Biol Psychiatry 39:1000-1008.
3. Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathé JM, Svensson TH. 1995. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. Naunyn Schmiedebergs Arch Pharmacol 352:374-385.
4. 1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol 347:353-362.
5. 2A antagonist MDL100907 on midbrain dopamine (DA) neurons in rats: an electrophysiological study. Am Soc Neurosci Abstr 22:1323.
6. 2B, receptors. Behav Brain Res 73:149-152.
7. Boess FG, Martin IL. 1994. Molecular biology of 5-HT receptors. Neuropharmacology 33:275-317.
8. 2C. receptors. BrJ Pharmacol 115:622-628.
9. Borowski TB, Kokkinidis L. 1996. Contribution of ventral tegmental area dopamine neurons to expression of conditional fear: effects of electrical stimulation, excitotoxin lesions, and quinpirole infusion on potentiated startle in rats. Behav Neurosci 110:1349-1364.
10. 2C. receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indenol[1,2-b|pyrrol-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. J Med Chem 40: 2762-2769.
11. Brodie MS, Bunney EB. 1996. Serotonin potentiates dopamine inhibition of ventral tegmental area neurons in vitro. J Neurophysiol 76:2077-2082.
12. Caldelcott-Hazard S, Morgan DG, Deleon-Jones F, Overstreet DH, Janowsky D. 1991. Clinical and biochemical aspects of depressive disorders. II. Transmitter/receptor theories. Synapse 9:251-301.
13. Cameron DL, Wessendorf MW, Williams JT. 1997. A subset of ventral tegmental area neurons is inhibited by dopamine, 5-hydroxytryptamine and opioids. Neuroscience 77:155-166.
14. 3 receptor activation in medial prefrontal cortex of freely moving rats. Synapse 10:264-266.
15. Chiang C, Aston-Jones G. 1993. A 5-hydroxytryptamine2 agonist augments γ-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neuroscience 54:409-420.
16. Clement HW, Gemsa D, Wesemann W. 1992. Serotonin-norepinephrine interactions: a voltammetric study on the effect of serotonin receptor stimulation followed in the N. raphe dorsalis and the locus coeruleus of the rat. J Neural Transm 88:11-23.
17. 2-like receptor-mediated depolarization of 5-HT-containing dorsal raphe neurones in vitro. Br J Pharmacol 120:261P.
18. 3 receptors. J Neurosci 18:6528-6538.
19. 2C receptor agonist, Ro 60-0175: a pharmacological analysis. Neuropharmacology 38:415-423.
20. Dewey SL, Smith GS, Logan J, Alexoff D, Ding Y-S, King P, Pappas N, Brodie JD, Ashby CR. 1995. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15:821-829.
21. 2C/2B receptors enhances mesolimbic and mesocortical dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91:587-597.
22. Di Mascio M, Di Giovanni G, Di Matteo V, Esposito E. 1998. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Br Res Bull 46:547-554.
23. 2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology 37:265-272.
24. 1D/1B receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 356:328-334.
25. 2 receptor activation decreases noradrenaline release in rat hippocampus in vivo. Br J Pharmacol 107:240-245.
26. 2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology 33:411-421.
27. 2C receptor messenger RNA in the basal ganglia of adult rats. J Comp Neurol 384:233-247.
28. B receptors. Naunyn Schmiedebergs Arch Pharmacol 357:611-619.
29. 2B receptor antagonist. J Med Chem 38:855-857.
30. Garratt JC, Kidd EJ, Wright IK, Marsden CA. 1991. Inhibition of 5-hydroxytryptamine neuronal activity by the 5-HT agonist, DOI. Eur J Pharmacol 199:349-355.
31. 2A receptor activation enhances dialysate levels of dopamine (DA) and noradrenaline (NA), but not 5-HT, in the frontal cortex (FCX) of freely-moving rats. Neuropharmacology 38:315-317.
32. 1B receptors with WAY 100,635 and GR 127,935. J Neurochem 68:1159-1163.
33. Gobert A, Rivet J-M, Audinot V, Newman-Tancredi A, Cistarelli L, Millan MJ. 1998. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and hetero-receptor mediated control of release. Neuroscience 84:413-429.
34. 2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Exp Ther 249:673-680.
35. Gresch PJ, Sved AF, Zigmond MJ, Finlay JM. 1995. Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem 65:111-116.
36. 2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology 36:793-802.
37. Haddjeri N, de Montigny C, Blier P. 1997. Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxytryptamine system. Br J Pharmacol 120:865-875.
38. 2-adrenoceptor antagonist. Neuropsychopharmacology 17:44-55.
39. Hervé D, Pickel VM, Joh TH, Beaudet A. 1987. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res 435:71-83.
40. 2A/2C receptor agonist potentiates amphetamine-induced dopamine release in rat striaturn. Brain Res 698:204-208.
41. Ichikawa J, Kuroki T, Dai J, Meltzer HY. 1998. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol 351:163-171.
42. Iyer RN, Bradberry CW. 1996. Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther 277:40-47.
43. 1C. receptors and antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 18:563-574.
44. B synaptic potential in rat dopamine neurones. J Neurosci 12:2000-2006.
45. Kelland MD, Chiodo LA. 1996. Serotoninergic modulation of midbrain dopamine systems. In: Ashby CR Jr, editor. The modulation of dopaminergic neurotransmission by other neurotransmitters. New York: CRC Press 87-122.
46. 2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 117:427-434.
47. 2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology 36:233-239.
48. 2C. receptor antagonist. Neuropharmacology 36:609-620.
49. Knable MB, Weinberger DR. 1997. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 11:123-131.
50. 2B receptor. Mol Pharmacol 46:227-234.
51. 2C receptor in rat choroid plexus. Neuropsychopharmacology 15:143-151.
52. 1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse 30:1-9.
53. 2C receptors modulate the activity of mesocortical and mesolimbic dopaminergic pathways: a combined dialysis and electrophysiological analysis. Am Soc Neurosci Abstr 23:975.
54. 1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats. J Pharmacol Exp Ther 280:1241-1249.
55. Leonard BE. 1997. The role of noradrenaline in depression: a review. J Psychopharmacol 11:S39-S47.
56. Maes M, Meltzer HY. 1995. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation in progress. New York: Raven Press, p 933-944.
57. 2C receptor agonists and antagonists in animal models of anxiety. Eur Neuropsychopharmacol Abstr 5:S4-S17.
58. 1A antagonists. J Pharmacol Exp Ther 268:337-352.
59. 2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 275:885-898.
60. 2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity. J Pharmacol Exp Ther 282:132-147.
61. 2Creceptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. Eur J Pharmacol 325:9-12.
62. 2c receptors tonically inhibit dopamine (DA) and noradrenaline (NAD), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37:953-955.
63. 1B receptors to G-protein coupling and function in corticolimbic structures in vivo. Neuropsychopharmacology 21:S61-S67.
64. 2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur Neuropsychopharmacol 6:169-175.
65. Overton PG, Clark D. 1997. Burst firing in midbrain dopaminergic neurons. Brain Res Rev 25:312-334.
66. 3 mediated control of dopaminergic function. Psychopharmacology 112:360-867.
67. 2C receptor. Psychopharmacology 126:234-240.
68. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates. Sydney, Australia: Academic Press.
69. Pazos A, Palacios JM. 1985. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 346:231-249.
70. Pazos A, Cortés R, Palacios JM. 1985. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346:205-230.
71. 2B/c ligands on in vivo dopamine release in the rat prefrontal cortex. Am Soc Neurosci Abstr 24:108.
72. Pennington NJ. 1996. Actions of methoxylated amphetamine hallucinogens on serotonergic neurons of the brain. Prog Neuropsychopharmacol Biol Psychiatry 20:951-965.
73. Pessia M, Jiang ZG, North RA, Johnson SW. 1994. Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res 654:324-330.
74. 2C receptors. Mol Brain Res 23:163-178.
75. Prisco S, Esposito E. 1995. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br J Pharmacol 116:1923-1931.
76. Prisco S, Pagannone S, Esposito E. 1994. Serotonin-dopamine interaction in the ventral tegmental area: an electrophysiological study in vivo. J Pharmacol Exp Ther 271:83-90.
77. 2 antagonists. Brain Res 385:395-400.
78. 2 binding affinity. Neuropsychopharmacology 1:101-107.
79. 2C receptors. Neuroscience 69:903-913.
80. Rivet J-M, Gobert A, Cistarelli L, Melon C, Millan MJ. 1998. Antidepressants (ADs) differentially modify dialysate serotonin (5-HT), dopamine (DA) and noradrenaline (NAD) levels in rats. Am Soc Neurosci Abstr 24:1114.
81. 2 receptor ligands modulate the behaviour of mice in the elevated plus-maze. Pharmacol Biochem Behav 49:985-995.
82. 1A receptor activation. Eur J Pharmacol 338:R3-R5.
83. Roth BL, Meltzer HY. 1995. The role of serotonin in schizophrenia. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation in progress. New York: Raven Press. p 1215-1228.
84. Saito H, Matsumoto M, Togashi H, Yoshioka M. 1996. Functional interaction between serotonin and other neuronal systems: focus on in vivo microdialysis studies. Jpn J Pharmacol 70:203-225.
85. Schatzberg AF, Schildkraut JJ. 1995. Recent studies on norepinephrine systems in mood disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation in progress. New York: Raven Press. p 911-920.
86. 2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 273:273-279.
87. 2 receptors redudes the increase in extracellular concentrations of dopamine produced the amphetamine analogue, 3,4-methylenedioxymethamphetamine. J Neurochem 62:1382-1398.
88. Schreiber R, Brocco M, Millan MJ. 1994. Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur J Pharmacol 264: 99-102.
89. 1A agonists. J Pharmacol Exp Ther 273:101-112.
90. 2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons. J Pharmacol Exp Ther 274:735-740.
91. 2 receptor antagonist MDL100907 as a putative atypical anti-psychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266:684-691.
92. 3 receptors. Am Soc Neurosci Abstr 23:2326.
93. 2C receptor subtypes in the control of haloperidol-induced release of dopamine in the rat striaturn. Am Soc Neurosci Abstr 24:108.
94. Sperling W, Demling J. 1997. New tetracyclic antidepressants. Drugs Today 33:95-102.
95. 2C receptors, on GABA-mediated synaptic input to rat substantia nigra pars reticulata neurons in vitro. J Neurosci 16:7566-7573.
96. 1-adrenoceptor antagonism. J Clin Psychopharmacol 15:11S-18S.
97. Tanda G, Carboni E, Frau R, Di Chiara G. 1994. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology 115:285-288.
98. 2C receptor antagonist SB 206553 and paroxetine. Br J Pharmacol 120:257P.
99. Trent F, Tepper JM. 1991. Dorsal raphe stimulation modifies striatalevoked antidromic invasion of nigral dopaminergic neurons in vivo. Exp Brain Res 84:620-630.
100. 3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther 271:1558-1565.
101. Wadenberg ML. 1996. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 20:325-339.
102. Westphal RS, Sanders-Bush E. 1994. Reciprocal binding properties of 5-hydroxytryptamine. Mol Pharmacol 46:937-942.
103. 2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens. Brain Res 781:291-299.
104. Willner P. 1995. Dopaminergic mechanisms in depression and mania In: Bloom FE, Kupfer DJ, editors Psychopharmacology: the fourth generation in progress. New York: Raven Press. p 921-931.
105. 2 receptor subtype mRNAs in rat brain. J Comp Neurol 351:357-373.
106. Zacharko RM, Anisman H. 1991. Stressor-induced anhedonia in the mesocorticolimbic system. Neurosci Biobehav Rev 15:391-405.